155 related articles for article (PubMed ID: 9890546)
21. [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Koshida H; Kametani T; Masuda S
Gan To Kagaku Ryoho; 1999 May; 26(6):833-6. PubMed ID: 10410154
[TBL] [Abstract][Full Text] [Related]
22. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Gurney H; Kefford R; Stuart-Harris R
Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
[TBL] [Abstract][Full Text] [Related]
23. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
[TBL] [Abstract][Full Text] [Related]
24. Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.
Newrick PG; Braatvedt GD; Webb AJ; Sheffield E; Corrall RJ
Postgrad Med J; 1994 Mar; 70(821):231-2. PubMed ID: 8183761
[TBL] [Abstract][Full Text] [Related]
25. Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.
Boumans D; de Vries PA; Rikken NE; Laverman GD
Neth J Med; 2013 Oct; 71(8):442-3. PubMed ID: 24127509
[No Abstract] [Full Text] [Related]
26. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
27. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Culbert EC; Schfirin BS
Obstet Gynecol; 2006 Sep; 108(3 Pt 2):789-91. PubMed ID: 17018504
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Grutters JC; Hermus AR; de Mulder PH; Beex LV
Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
[TBL] [Abstract][Full Text] [Related]
29. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
30. Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients.
Chong G; Hoang T; Davis ID
Aust N Z J Med; 1999 Feb; 29(1):96-7. PubMed ID: 10200826
[No Abstract] [Full Text] [Related]
31. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
[TBL] [Abstract][Full Text] [Related]
32. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Gurney H; Grill V; Martin TJ
Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
[TBL] [Abstract][Full Text] [Related]
33. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Dodwell DJ; Abbas SK; Morton AR; Howell A
Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
[TBL] [Abstract][Full Text] [Related]
34. Symptomatic hypocalcemia after intravenous pamidronate.
McIntyre E; Bruera E
J Palliat Care; 1996; 12(1):46-7. PubMed ID: 8857248
[TBL] [Abstract][Full Text] [Related]
35. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Lipton A; Porter L; Blayney D; Sinoff C; Wheeler H; Simeone JF; Seaman JJ; Knight RD; Heffernan M; Mellars K; Reitsma DJ
J Clin Oncol; 1998 Jun; 16(6):2038-44. PubMed ID: 9626201
[TBL] [Abstract][Full Text] [Related]
36. [Therapy of hypercalcemia with ibandronate in case of acute renal failure].
Bergner R; Henrich DM; Hoffmann M; Bruckner D; Uppenkamp M
Internist (Berl); 2006 Mar; 47(3):293-6. PubMed ID: 16470360
[TBL] [Abstract][Full Text] [Related]
37. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Wimalawansa SJ
Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
[TBL] [Abstract][Full Text] [Related]
38. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
39. Acute presentation of a giant intrathyroidal parathyroid adenoma: a case report.
Rutledge S; Harrison M; O'Connell M; O'Dwyer T; Byrne MM
J Med Case Rep; 2016 Oct; 10(1):286. PubMed ID: 27756436
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
